The Beauty Health Company (NASDAQ:SKIN) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of The Beauty Health Company (NASDAQ:SKIN) have received an average recommendation of “Reduce” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $5.39.

A number of brokerages have commented on SKIN. Piper Sandler reissued an “underweight” rating and issued a $1.00 price objective (down from $1.50) on shares of Beauty Health in a research note on Friday, August 9th. TD Cowen reduced their price objective on Beauty Health from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Monday, May 13th. Stifel Nicolaus lowered their target price on Beauty Health from $4.00 to $2.00 and set a “hold” rating for the company in a report on Friday, July 26th. DA Davidson restated a “buy” rating and set a $5.00 price target on shares of Beauty Health in a research note on Monday, May 13th. Finally, Canaccord Genuity Group decreased their price objective on Beauty Health from $2.00 to $1.25 and set a “hold” rating for the company in a report on Monday, August 12th.

Beauty Health Stock Performance

NASDAQ SKIN opened at $1.73 on Friday. The business has a 50 day simple moving average of $1.73 and a two-hundred day simple moving average of $2.70. Beauty Health has a 1-year low of $0.91 and a 1-year high of $7.23. The company has a debt-to-equity ratio of 7.96, a current ratio of 6.49 and a quick ratio of 5.47. The stock has a market capitalization of $213.88 million, a PE ratio of -2.47 and a beta of 0.96.

Insiders Place Their Bets

In other news, Chairman Brent L. Saunders purchased 40,450 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $1.08 per share, for a total transaction of $43,686.00. Following the acquisition, the chairman now owns 5,921,769 shares of the company’s stock, valued at $6,395,510.52. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 41.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Beauty Health

Several hedge funds and other institutional investors have recently made changes to their positions in SKIN. HighMark Wealth Management LLC acquired a new position in shares of Beauty Health in the first quarter valued at about $31,000. Raymond James & Associates acquired a new position in Beauty Health in the 4th quarter worth approximately $31,000. Raymond James Financial Services Advisors Inc. purchased a new position in Beauty Health during the 4th quarter worth approximately $31,000. SageView Advisory Group LLC acquired a new stake in Beauty Health during the 1st quarter valued at approximately $60,000. Finally, Caprock Group LLC purchased a new stake in shares of Beauty Health in the 2nd quarter valued at $38,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.